{"id":"NCT00344370","sponsor":"Kowa Research Europe","briefTitle":"Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia","officialTitle":"Double-Blind, Follow-On Study of Pitavastatin (4 mg) Versus Atorvastatin (20 mg and 40 mg), With a Single-Blind Extension of Treatment, in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-08","primaryCompletion":"2008-04","completion":"2008-04","firstPosted":"2006-06-26","resultsPosted":"2010-01-18","lastUpdate":"2010-02-02"},"enrollment":214,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type II Diabetes Mellitus","Dyslipidemia"],"interventions":[{"type":"DRUG","name":"Pitavastatin","otherNames":["Livalo"]},{"type":"DRUG","name":"Atorvastatin","otherNames":["Lipitor"]}],"arms":[{"label":"Pitavastatin","type":"EXPERIMENTAL"},{"label":"Atorvastatin","type":"ACTIVE_COMPARATOR"}],"summary":"This is a sixteen-week double-blind active-controlled follow-on and 28-week single-blind extension study for patients who participated in study NK-104-305.","primaryOutcome":{"measure":"NCEP LDL-C Target Attainment","timeFrame":"44 weeks","effectByArm":[{"arm":"Pitavastatin 4 mg","deltaMin":110,"sd":null},{"arm":"Atorvastatin 40 mg","deltaMin":55,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":35,"countries":["Denmark","Germany","India","Netherlands","Poland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":143},"commonTop":["Naspopharyngitis","Myalgia/myalgia intercostal","Arteriosclerosis","Diabetes mellitus inadequate control"]}}